RPS6KB1
Ribosomal protein S6 kinase beta-1
As of the edition of 20 October 2026, RPS6KB1 (ribosomal protein S6 kinase beta-1, UniProt P23443) has 5 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23443
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 22
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Blood and lymph; Immune system; Lungs and airways; Pregnancy and women's health
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 3 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| LY-2584702 | Went quiet | Phase 1 | none listed |
| LY-2780301 | Stopped | Phase 2 | none listed |
| Rupitasertib | Went quiet | Phase 1 | none listed |
| TAS0612 | Stopped | Phase 1 | none listed |
| XL-418 | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
The other 1 company at RPS6KB1
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at RPS6KB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.